| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.091 | 0.003 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.003 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.17 | 0.004 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.085 | 0.004 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.005 |